Back to top

Image: Bigstock

Is Bioventus (BVS) Stock Undervalued Right Now?

Read MoreHide Full Article

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.

Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.

One stock to keep an eye on is Bioventus (BVS - Free Report) . BVS is currently sporting a Zacks Rank #2 (Buy) and an A for Value. The stock is trading with P/E ratio of 11.54 right now. For comparison, its industry sports an average P/E of 33.85. Over the past year, BVS's Forward P/E has been as high as 31.00 and as low as 8.75, with a median of 14.38.

Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. BVS has a P/S ratio of 2.01. This compares to its industry's average P/S of 3.22.

Finally, we should also recognize that BVS has a P/CF ratio of 9.42. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. BVS's P/CF compares to its industry's average P/CF of 12.77. BVS's P/CF has been as high as 110.14 and as low as 8.34, with a median of 37.60, all within the past year.

These figures are just a handful of the metrics value investors tend to look at, but they help show that Bioventus is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, BVS feels like a great value stock at the moment.

Published in